Market Research

Inflammatory Bowel Disease Treatment Market Forecasts to 2030 – Global Analysis By Type (Ulcerative Colitis and Crohn's Disease), Drug Class, Route of Administration, Distribution Channel and By Geography

Best Price Guarantee Length Publisher Published Date SKU
from $4,150 175 Pages Stratistics Market Research Consulting August, 2023 SMR18145665
Best Price Guarantee
Price from $4,150
Length 175 Pages
Publisher Stratistics Market Research Consulting
Published Date August, 2023
SKU SMR18145665

Inflammatory Bowel Disease Treatment Market Forecasts to 2030 – Global Analysis By Type (Ulcerative Colitis and Crohn's Disease), Drug Class, Route of Administration, Distribution Channel and By Geography According to Stratistics MRC, the Global Inflammatory Bowel Disease Treatment Market is accounted for $21.47 billion in 2023 and is expected to reach $31.44 billion by 2030 growing at a CAGR of 5.6% during the forecast period. The term ""inflammatory bowel disease"" (IBD) is used to describe ulcerative colitis and Crohn's disease, two conditions in which the GI tract is chronically inflamed. The digestive system becomes damaged over time by inflammation. The goal of treating irritable bowel syndrome is to reduce the inflammation that is the source of your signs and symptoms. In the best-case scenario, this might lead to symptom relief, a long-term remission, and lowered complications risks. For the treatment of IBD, drugs or surgery are usually employed.

According to ClinicalTrials.gov., there are currently 965 clinical trials being undertaken in the United States alone out of the 2,784 clinical trials (including medication development, observational studies, and others) connected to IBD.

Market Dynamics:

Driver:

Increasing prevalence of disease is presenting a large patient pool undergoing treatment

Many factors, including genetic predisposition, environmental triggers, and immune system disturbances, are responsible for the rising prevalence of ulcerative colitis and Crohn's disease. The majority of individuals who have ulcerative colitis or Crohn's disease have a family history of the condition. By educating the public about these diseases' symptoms, diagnoses, and treatments, a number of government agencies are raising public awareness of these illnesses. Therefore, it is projected that growing consumer awareness of various treatment alternatives and rising disease diagnosis rates in developing nations will boost market expansion.

Restraint:

High cost

In underdeveloped nations, there is a lack of knowledge regarding inflammatory bowel disease, which lowers the number of individuals receiving treatment. Additionally, it is anticipated that high treatment costs, including those associated with drugs and other expenses, may restrict the use of an inflammatory bowel disease treatment among patients. Additionally, biologics are being used more frequently to treat ulcerative colitis and Crohn's disease, but the market expansion is being constrained by the high costs of biologic treatment.

Opportunity:

Strong portfolio of pipeline molecules to increase product launches

Some of the reasons driving the growth of the inflammatory bowel disease treatment market include the rising prevalence of Crohn's disease and ulcerative colitis, as well as increased awareness of the condition on a global scale. As a result, a number of important industry firms are concentrating on R&D and looking into new prospective candidates for the treatment of IBD.

Threat:

Limited pipeline of new drugs and technical challenges

The number of new medications being developed to treat IBD is rather small, and most of them focus on similar mechanisms of action. The pharmaceutical industry may find it harder to differentiate its medicines as a result, which may put pressure on prices. A number of laws, including those governing clinical trials, labeling, and safety monitoring, pertain to the IBD market. For pharmaceutical companies, complying with these rules can be time- and money-consuming.

Covid-19 Impact:

The market for treating inflammatory bowel disease expanded more slowly during the predicted period as a result of COVID-19's effects. The closure of diagnostic facilities, travel restrictions, and lockdowns in numerous nations worldwide are a few of the causes contributing to the disease's delayed rate of treatment. The revenue generated in 2020 was significantly lower than it was in 2019.

The crohn’s disease segment is expected to be the largest during the forecast period

The Crohn’s disease segment is expected to hold the largest share during the forecast period. The rising incidence of Crohn's disease and the number of people undergoing treatment for it internationally are both credited with driving the expansion of this market. For instance, according to the Deutsches Arztblatt, there are 100 to 200 cases of Crohn's disease per 100,000 people in Germany.

The injectables segment is expected to have the highest CAGR during the forecast period

Due to rising product approvals for biologics as well as rising biologic usage for the treatment of ulcerative colitis and Crohn's disease, the injectables sector is anticipated to have the highest CAGR over the projection period. For instance, AbbVie Inc. announced in February 2021 that the FDA had approved HUMIRA for the treatment of moderate to severe active ulcerative colitis in juvenile patients. Through subcutaneous injections, HUMIRA is administered. Thus, the expansion of the injectables sector is supported by the rising demand for biologics for the treatment of IBD.

Region with largest share:

North America dominated the global market for the treatment of inflammatory bowel disease as a result of the existence of numerous powerful market players and the numerous strategic initiatives they carried out there. Additionally, the region's improved reimbursement practices, high treatment rates, and rising prescription of innovative treatments are aiding regional expansion. The region's expansion is also predicted to be fueled by continuous efforts to discover innovative therapies and supportive government initiatives.

Region with highest CAGR:

Over the forecast period, Asia-Pacific is expected to experience the highest growth. Some of the key reasons driving market expansion in the upcoming years include an aging population, a high chance of developing inflammatory diseases, an increase in the prevalence of inflammatory bowel diseases, and better healthcare policies in the area. Additionally, increased investments by top players in the region and the increasing acceptance of biosimilars and biologics are anticipated to fuel market expansion in the near future.

Key players in the market

Some of the key players in Inflammatory Bowel Disease Treatment market include Allergan plc., Janssen Biotech, Celltrion Inc., Pfizer Inc, Merck & co., inc, Bristol-myers squibb company, Bausch health companies inc, Takeda Pharmaceutical Company Limited, Novartis AG, UCB S.A., Amgen Inc, Johnson & Johnson Services, Inc, Biogen and AbbVie Inc.

Key Developments:

In October 2021, Bristol-Myers Squibb Company announced the approval of Zeposia (ozanimod) by the Committee for Medicinal Products for Human Use (CHMP) for the treatment of adults with moderately to severely active Ulcerative Colitis (UC).

In February 2021, the European Commission (EC) granted marketing authorization to CELLTRION INC.’s Yuflyma biosimilar used to treat adult and pediatric Crohn’s disease and ulcerative colitis.

Types Covered:
• Ulcerative Colitis
• Crohn's Disease

Drug Class Covered:
• JAK inhibitors
• Anti-integrin
• IL inhibitors
• TNF inhibitors
• Corticosteroids
• Aminosalicylates
• Other Drug Class

Route of Administrations Covered:
• Injectable
• Oral

Distribution Channels Covered:
• Online Pharmacy
• Retail Pharmacy
• Hospital Pharmacy

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements


1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Inflammatory Bowel Disease Treatment Market, By Type
5.1 Introduction
5.2 Ulcerative Colitis
5.3 Crohn's Disease
6 Global Inflammatory Bowel Disease Treatment Market, By Drug Class
6.1 Introduction
6.2 JAK inhibitors
6.3 Anti-integrin
6.4 IL inhibitors
6.5 TNF inhibitors
6.6 Corticosteroids
6.7 Aminosalicylates
6.8 Other Drug Class
7 Global Inflammatory Bowel Disease Treatment Market, By Route of Administration
7.1 Introduction
7.2 Injectable
7.3 Oral
8 Global Inflammatory Bowel Disease Treatment Market, By Distribution Channel
8.1 Introduction
8.2 Online Pharmacy
8.3 Retail Pharmacy
8.4 Hospital Pharmacy
9 Global Inflammatory Bowel Disease Treatment Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Allergan plc.
11.2 Janssen Biotech
11.3 Celltrion Inc.
11.4 Pfizer Inc
11.5 Merck & co., inc
11.6 Bristol-myers squibb company
11.7 Bausch health companies inc
11.8 Takeda Pharmaceutical Company Limited
11.9 Novartis AG
11.10 UCB S.A.
11.11 Amgen Inc
11.12 Johnson & Johnson Services, Inc
11.13 Biogen
11.14 AbbVie Inc.,
List of Tables
Table 1 Global Inflammatory Bowel Disease Treatment Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
Table 3 Global Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
Table 4 Global Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
Table 5 Global Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
Table 6 Global Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
Table 7 Global Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
Table 8 Global Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
Table 9 Global Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
Table 10 Global Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
Table 11 Global Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
Table 12 Global Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
Table 13 Global Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 14 Global Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
Table 15 Global Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
Table 16 Global Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 17 Global Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 18 Global Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 19 Global Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 20 North America Inflammatory Bowel Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
Table 21 North America Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
Table 22 North America Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
Table 23 North America Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
Table 24 North America Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
Table 25 North America Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
Table 26 North America Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
Table 27 North America Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
Table 28 North America Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
Table 29 North America Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
Table 30 North America Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
Table 31 North America Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
Table 32 North America Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 33 North America Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
Table 34 North America Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
Table 35 North America Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 36 North America Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 37 North America Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 38 North America Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 39 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
Table 40 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
Table 41 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
Table 42 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
Table 43 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
Table 44 Europe Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
Table 45 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
Table 46 Europe Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
Table 47 Europe Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
Table 48 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
Table 49 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
Table 50 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
Table 51 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 52 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
Table 53 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
Table 54 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 55 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 56 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 57 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 58 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
Table 59 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
Table 60 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
Table 61 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
Table 62 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
Table 63 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
Table 64 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
Table 65 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
Table 66 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
Table 67 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
Table 68 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
Table 69 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
Table 70 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 71 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
Table 72 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
Table 73 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 74 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 75 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 76 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 77 South America Inflammatory Bowel Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
Table 78 South America Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
Table 79 South America Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
Table 80 South America Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
Table 81 South America Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
Table 82 South America Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
Table 83 South America Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
Table 84 South America Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
Table 85 South America Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
Table 86 South America Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
Table 87 South America Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
Table 88 South America Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
Table 89 South America Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 90 South America Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
Table 91 South America Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
Table 92 South America Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 93 South America Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 94 South America Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 95 South America Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 96 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
Table 97 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
Table 98 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
Table 99 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
Table 100 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
Table 101 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
Table 102 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
Table 103 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
Table 104 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
Table 105 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
Table 106 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
Table 107 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
Table 108 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 109 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
Table 110 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
Table 111 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 112 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 113 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 114 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)

$4,150
$7,500

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings